Studying nerve-muscle organoids for refractory myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study uses lab-grown mini muscle-nerve cells (organoids) to better understand severe, hard-to-treat myasthenia gravis. It may help researchers find new treatment options for people with the AChR antibody type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of generalized myasthenia gravis with positive AChR antibodies.
- You have had your disease and treatment tracked for at least 12 months (or are newly diagnosed).
- You agree to sign a consent form to take part (and to allow use of stored samples if applicable).
- You do not have other autoimmune disorders or neuromuscular diseases, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses wearable sensors and smartphone apps to track your myasthenia gravis symptoms over time. It aims to see how well these technologies can measure your condition in daily life, which could help you and your doctor manage your care better.
This study looks for markers that might predict who will respond well to a new class of medicines called FcRn inhibitors. These medicines help reduce harmful antibodies that attack nerves and muscles in people with a certain type of Myasthenia Gravis. The goal is to better personalize treatment for patients in Italy.
This study follows people with suspected or confirmed myasthenia gravis (a condition that causes muscle weakness that gets worse with use). It uses several specialized nerve and antibody tests to make a more precise diagnosis and tracks you over time to see how well these methods work.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests an experimental oral medication called NMD670 for people with myasthenia gravis (MG). It aims to see if the drug is safe and if it helps improve muscle strength and daily function.
This study tests a new drug called SHR-2173 to help people with generalized myasthenia gravis (a condition where muscles weaken because the immune system blocks communication between nerves and muscles). The drug is designed to work with treatments you're already taking to improve muscle strength and reduce symptoms.
Hear when a new Myasthenia Gravis Generalized trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.